Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Central Serous Chorioretinopathy Clinical Trial

Official title: Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.

Clinical Trial Description

This is an open-label, Phase I study of intravitreally administered ranibizumab in subjects with unresolving CSC and subfoveal fluid. Patients will be evaluated at baseline with ophthalmic examination, fluorescein angiography, optical coherence tomography, and color photography. Subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered every 28 days (± 2 days) for 3 injections. Thereafter they are to be evaluated every month until month 12. Treatment will be administered to patients if there is presence of active leakage as determined by fluorescein angiography or persistence presence of sub retinal fluid upon OCT examination at that monthly visit. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy

• NCT number: NCT00403325
• Study type: Interventional
• Source: Vitreous -Retina- Macula Consultants of New York
• Status: Completed
• Phase: Phase 1
• Start date: August 2006